University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

David Jablons, M.D.

Chief of Thoracic Surgery

Dr. David M. Jablons is a renowned lung cancer expert, chief of General Thoracic Surgery at UCSF Medical Center and program leader of the Thoracic Oncology Program of the UCSF Helen Diller Family Comprehensive Cancer Center. He also is director of the UCSF Thoracic Oncology Laboratory where he is investigating molecular biology and genomics.

Jablons earned an undergraduate degree from Yale University and a medical degree from Albany Medical College of Union University. He completed a surgical residency at Tufts-New England Medical Center. He has written numerous research papers and frequently lectures about lung cancer at international and national meetings. He is a member of many professional organizations, including the American Association for Cancer Research, International Association for the Study of Lung Cancer, Society of Thoracic Surgeons and the American Association for the Advancement of Science.

Clinics

Thoracic Surgery and Oncology
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 885-3882
Fax: (415) 353-9525

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about David Jablons

Additional Languages

Chinese
French
Russian
Spanish

Education

Albany Medical College 1984

Residencies

Tufts-New England Medical Center, General Surgery 1991

Fellowships

New York Hospital-Cornell University, Cardiothoracic Surgery 1993

Selected Research and Publications

  1. Fang LT, Lee S, Choi H, Kim HK, Jew G, Kang HC, Chen L, Jablons D, Kim IJ. Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis. Int J Oncol. 2014 Jan; 44(1):211-21.
  2. Zhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J. VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer. J Thorac Dis. 2013 Oct; 5(5):578-84.
  3. Hung MS, Xu Z, Chen Y, Smith E, Mao JH, Hsieh D, Lin YC, Yang CT, Jablons DM, You L. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. Int J Oncol. 2013 Nov; 43(5):1517-22.
  4. Mo ML, Okamoto J, Chen Z, Hirata T, Mikami I, Bosco-Clément G, Li H, Zhou HM, Jablons DM, He B. Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma. PLoS One. 2013; 8(8):e71816.
  5. Lau D, Yarlagadda J, Jahan T, Jablons D, Chou D. Desmoplastic fibroma of the spine causing severe mediastinal compression and brachial plexus encasement: report of 2 cases. J Neurosurg Spine. 2013 Oct; 19(4):515-20.
  6. Ganesan AP, Johansson M, Ruffell B, Beltran A, Lau J, Jablons DM, Coussens LM. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 2013 Aug 15; 191(4):2009-17.
  7. Liu S, Hsieh D, Yang YL, Xu Z, Peto C, Jablons DM, You L. Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2. BMC Pharmacol Toxicol. 2013; 14:36.
  8. Bravo DT, Yang YL, Kuchenbecker K, Hung MS, Xu Z, Jablons DM, You L. Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer. BMC Cancer. 2013; 13:316.
  9. Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, Hurst JW, Segal MR, Berryman DM, Chu W, He B, Jablons DM, Mann MJ. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol. 2013 Jun; 22(2):65-9.
  10. Mo ML, Chen Z, Zhou HM, Li H, Hirata T, Jablons DM, He B. Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer. J Exp Clin Cancer Res. 2013; 32:29.
  11. Zhang S, Long H, Yang YL, Wang Y, Hsieh D, Li W, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. Inhibition of CK2a down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med. 2013 Jul; 17(7):854-62.
  12. Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B. Gli as a novel therapeutic target in malignant pleural mesothelioma. PLoS One. 2013; 8(3):e57346.
  13. Mann MJ, Jablons DM, Kratz JR. Prognostic assay in small, node-negative non-small cell lung cancer--reply. JAMA. 2013 Feb 27; 309(8):769-70.
  14. Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N. SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013; 32:7.
  15. Tsao MS, Jablons DM. Molecular prognostication of non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2013; 25(1):4-7.
  16. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun. 2013; 4:1701.
  17. Xi Y, Wei Y, Sennino B, Ulsamer A, Kwan I, Brumwell AN, Tan K, Aghi MK, McDonald DM, Jablons DM, Chapman HA. Identification of pY654-ß-catenin as a critical co-factor in hypoxia-inducible factor-1a signaling and tumor responses to hypoxia. Oncogene. 2013 Oct 17; 32(42):5048-57.
  18. Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. BMJ Open. 2012; 2(6).
  19. Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B. The role of stem cells in airway repair: implications for the origins of lung cancer. Chin J Cancer. 2013 Feb; 32(2):71-4.
  20. Kratz JR, Van den Eeden SK, He J, Jablons DM, Mann MJ. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA. 2012 Oct 24; 308(16):1629-31.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.